Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21965366 | 0.86 | CRBN (0.70) | CRBNDDB1 | |
| SCHEMBL26328156 | 0.86 | CRBN (0.50) | CRBNDDB1 | |
| SCHEMBL26328179 | 0.85 | DDB1 (0.52) | CRBNDDB1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL26328245 | 0.85 | CRBN (0.49) | CRBNDDB1ALDH1A1TSHR | |
| SCHEMBL26328237 | 0.84 | DDB1 (0.54) | CRBNDDB1LMNAHTTSMN1; SMN2 | |
| SCHEMBL26328228 | 0.84 | CRBN (0.48) | CRBNDDB1 | |
| SCHEMBL26328207 | 0.84 | CRBN (0.57) | CRBNDDB1LMNAHTTALDH1A1 | |
| SCHEMBL26328227 | 0.83 | CRBN (0.56) | CRBNDDB1ALDH1A1 | |
| SCHEMBL26328225 | 0.82 | DDB1 (0.46) | CRBNDDB1 | |
| SCHEMBL26328226 | 0.80 | CRBN (0.46) | CRBNDDB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | CRBN 1/4885DDB1 319/4885LMNA 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.